Overview
OCUL market data
Price History
OCUL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.93 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.23 – $16.44 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.9K · P/B 3.95 · P/S 36.27.
Company news
Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in DevelopmentGlobenewswire Inc · Jul 3, 2026, 2:15 PM
Ocular Therapeutix™ to Participate in July Scientific and Investor ConferencesGlobenewswire Inc · Jul 1, 2026, 11:15 AM
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23Benzinga · Jun 25, 2026, 1:40 PM
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25Benzinga · Jun 18, 2026, 4:00 PM
Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30Benzinga · Jun 18, 2026, 1:15 PM
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug ProgramBenzinga · Jun 17, 2026, 3:00 PM
Trading Halt: Halt status updated at 9:10:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jun 17, 2026, 1:15 PM
Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028Benzinga · Jun 17, 2026, 12:50 PM
Trading Halt: Halted at 8:40:00 a.m. ET - Trading Halt: Halt News PendingBenzinga · Jun 17, 2026, 12:45 PM
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jun 15, 2026, 9:15 PM